Fig. 7.
The value of SMG5 and MRPL9 in predicting the prognosis and recurrence of HCC. A-B The expression of SMG5 (A) and MRPL9 (B) as assessed in Oncomine. C-D The expression of SMG5 (C) and MRPL9 (D) as assessed in GEPIA. E-F Survival analysis for SMG5 (E) and MRPL9 (F). G-H Recurrence analysis for SMG5 (G) and MRPL9 (H). I-J The correlation of the expression of SMG5 (I) and MRPL9 (J) with the infiltration of different immune cells.